AR065337A1 - Proceso para la sintesis de compuestos de 2- aminotiazol como inhibidores de quinasa, forma polimorfica - Google Patents
Proceso para la sintesis de compuestos de 2- aminotiazol como inhibidores de quinasa, forma polimorficaInfo
- Publication number
- AR065337A1 AR065337A1 ARP080100620A ARP080100620A AR065337A1 AR 065337 A1 AR065337 A1 AR 065337A1 AR P080100620 A ARP080100620 A AR P080100620A AR P080100620 A ARP080100620 A AR P080100620A AR 065337 A1 AR065337 A1 AR 065337A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- group
- trifluoromethyl
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Compuestos farmacéuticos que son utiles como determinados inhibidores de tirosina quinasa y más particularmente como inhibidores de c-kit y bcr-abl. Reivindicacion 1: Un proceso para elaborar un compuesto de formula 1, o una sal o un solvato deéste, donde R1 y R2 se seleccionan independientemente de hidrogeno, halogeno, un grupo alquilo o cicloalquilo recto o ramificado que contiene entre 1 y 10 átomos de carbono, trifluorometilo, alcoxi, ciano, dialquilamino y un grupo solubilizante, mes 0-5 y n es 0-4, R3 es uno de los siguientes: 1) un grupo arilo tal como fenilo o una variante sustituida de éste, que tiene cualquier combinacion, en cualquier posicion anular, de uno o varios sustituyentes tales como halogeno, grupos alquilo C1-10, trifluorometilo, ciano y alcoxi; 2) un grupo heteroarilo tal como un grupo 2-, 3- o 4-piridilo, que adicionalmente puede tener cualquier combinacion de uno o varios sustituyentes tales como halogeno, grupos alquilo C1-10, trifluorometilo yalcoxi; 3) un grupo heterocíclico aromático anular de cinco miembros tal como, por ejemplo, 2-tienilo, 3-tienilo, 2-tiazolilo, 4-tiazolilo, 5-tiazolilo, que adicionalmente puede tener cualquier combinacion de uno o varios sustituyentes tales comohalogeno, un grupo alquilo C1-10, trifluorometilo y alcoxi; que comprende los pasos que consisten en: a) la ciclacion a temperatura ambiente de un compuesto de formula (4), con un intermediario lnt4 de formula (5) donde Ra puede ser metilo,trifluorometilo, isopropilo o un fenilo opcionalmente sustituido, y R2, R3 y n son como se describieron anteriormente, para formar un compuesto de formula (3), donde R2, R3 y n son como se describieron anteriormente; b) la reduccion del grupo nitrode dicho compuesto de formula (3) para formar un compuesto de formula (2), donde R2, R3 y n son como se describieron anteriormente; c) el acoplamiento en un solvente aprotico de un compuesto de formula (2) con un compuesto de formula (6) donde Rb esun grupo hidroxilo, alcoxi o halogeno, y R1 y m son como se describieron anteriormente, para formar un compuesto de formula (1). Reivindicacion 22: Una forma polimorfica del compuesto (9), que permanece seca al 8O% de humedad relativa y estermodinámicamente estable a temperaturas inferiores a 200°C, caracterizada por un patron de difraccion de rayos X que comprende picos característicos a aproximadamente 7,269, 9,120, 11,038, 13,704, 14,481, 15,483, 15,870, 16,718, 17,087, 17,473,18,224, 19,248, 19,441, 19,940, 20,441, 21,469, 21,750, 22,111, 23,319, 23,763, 24,120, 24,681, 25,754, 26,777, 28,975, 29,609, 30,073 grados theta.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88958707P | 2007-02-13 | 2007-02-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR065337A1 true AR065337A1 (es) | 2009-06-03 |
Family
ID=39332208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080100620A AR065337A1 (es) | 2007-02-13 | 2008-02-13 | Proceso para la sintesis de compuestos de 2- aminotiazol como inhibidores de quinasa, forma polimorfica |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US8153792B2 (es) |
| EP (2) | EP2366703B1 (es) |
| JP (2) | JP5568312B2 (es) |
| KR (1) | KR20090110851A (es) |
| CN (2) | CN101657446B (es) |
| AR (1) | AR065337A1 (es) |
| AT (1) | ATE515506T1 (es) |
| AU (1) | AU2008214679A1 (es) |
| BR (1) | BRPI0807626B1 (es) |
| CA (2) | CA2970628C (es) |
| ES (2) | ES2522169T3 (es) |
| HR (2) | HRP20110709T1 (es) |
| IL (1) | IL200320A0 (es) |
| MA (1) | MA31180B1 (es) |
| MX (1) | MX2009008665A (es) |
| NZ (1) | NZ578944A (es) |
| PL (2) | PL2366703T3 (es) |
| RU (2) | RU2456285C2 (es) |
| SI (2) | SI2118099T1 (es) |
| TN (1) | TN2009000342A1 (es) |
| TW (1) | TWI406862B (es) |
| WO (1) | WO2008098949A2 (es) |
| ZA (1) | ZA200905981B (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050239852A1 (en) | 2002-08-02 | 2005-10-27 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| US8450302B2 (en) | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| WO2011092273A1 (en) | 2010-01-28 | 2011-08-04 | Ab Science | Treatment of gist with masitinib |
| WO2011092338A1 (en) | 2010-02-01 | 2011-08-04 | Ab Science | Combined treatment of pancreatic cancer with gemcitabine and masitinib |
| AR080380A1 (es) | 2010-03-09 | 2012-04-04 | Ab Science | Tratamiento de la demencia tipo alzheimer con masitinib |
| TW201204360A (en) | 2010-04-20 | 2012-02-01 | Ab Science | Treatment of multiple sclerosis with MASITINIB |
| TW201204719A (en) | 2010-06-02 | 2012-02-01 | Ab Science | Treatment of rheumatoid arthritis with masitinib |
| WO2012059526A1 (en) | 2010-11-05 | 2012-05-10 | Ab Science | Treatment of mastocytosis with masitinib |
| US10045978B2 (en) | 2010-11-05 | 2018-08-14 | Ab Science | Treatment of mastocytosis with masitinib |
| US9078894B2 (en) | 2011-02-04 | 2015-07-14 | Ab Science | Treatment of severe persistant asthma with masitinib |
| AR085934A1 (es) | 2011-04-08 | 2013-11-06 | Ab Science | Tratamiento de mieloma multiple con masitinib |
| JP6234466B2 (ja) | 2012-10-04 | 2017-11-22 | エービー サイエンス | 予測因子を用いて同定された患者サブ集団における癌の処置のためのマシチニブの使用 |
| TW201605449A (zh) | 2013-12-02 | 2016-02-16 | Ａｂ化學公司 | 馬賽替尼治療結腸直腸癌的用途 |
| EP2886543A1 (en) | 2013-12-18 | 2015-06-24 | Sandoz Ag | Crystalline form of mastinib mesylate |
| US20170196853A1 (en) | 2014-06-02 | 2017-07-13 | Ab Science | Use of an inhibitor of kinase activity, particularly masitinib, for treatment of prostate cancer |
| CN105585556A (zh) * | 2014-11-13 | 2016-05-18 | 连云港杰瑞药业有限公司 | 一种伊马替尼的合成方法 |
| CN106794179A (zh) * | 2015-07-29 | 2017-05-31 | 苏州晶云药物科技有限公司 | 马赛替尼甲磺酸盐的新晶型及其制备方法 |
| WO2017060308A1 (en) | 2015-10-05 | 2017-04-13 | Ab Science | Treatment of severe systemic mastocytosis with masitinib |
| CA3018635C (en) | 2016-03-25 | 2023-09-26 | Ab Science | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation |
| WO2018177854A1 (en) | 2017-03-31 | 2018-10-04 | Sandoz Ag | Crystalline form of masitinib |
| US10696638B2 (en) | 2017-12-26 | 2020-06-30 | Industrial Technology Research Institute | Compounds for inhibiting AGC kinase and pharmaceutical compositions comprising the same |
| US20230000838A1 (en) | 2019-11-22 | 2023-01-05 | Ab Science | Masitinib for the treatment of sickle cell disease |
| EP3831384A1 (en) | 2019-12-02 | 2021-06-09 | AB Science | Use of masitinib for the treatment of eosinophilic asthma |
| CN115515590A (zh) | 2020-02-20 | 2022-12-23 | Ab科学有限公司 | 马赛替尼用于治疗多发性硬化患者亚群 |
| KR20230014681A (ko) | 2020-04-10 | 2023-01-30 | 에이비 사이언스 | 코로나바이러스 질환 2019(covid-19)의 치료를 위한 마시티닙의 용도 |
| CA3201259A1 (en) | 2020-12-16 | 2022-06-23 | Alain Moussy | Masitinib for the treatment of alzheimer's disease |
| US20230321081A1 (en) | 2021-05-17 | 2023-10-12 | Ab Science | Masitinib for the treatment of castrate-resistant prostate cancer |
| CN115850258B (zh) * | 2022-12-27 | 2024-09-24 | 东北林业大学 | 一种马赛替尼的合成方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3299087A (en) * | 1961-04-24 | 1967-01-17 | Geigy Chem Corp | Nu, nu'-bis-(thiazolyl)-phenylenediamines |
| EP0983260A2 (en) * | 1997-05-22 | 2000-03-08 | G.D. Searle & Co. | 3(5)-HETEROARYL SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS |
| CO4940418A1 (es) * | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| CN1158269C (zh) * | 1997-10-27 | 2004-07-21 | 阿古龙制药公司 | 作为cdk抑制剂的取代的4-氨基-噻唑-2-基化合物 |
| US6114365A (en) * | 1999-08-12 | 2000-09-05 | Pharmacia & Upjohn S.P.A. | Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| WO2001017995A1 (en) * | 1999-09-10 | 2001-03-15 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US20050176687A1 (en) | 2001-06-29 | 2005-08-11 | Alain Moussy | Use of tyrosine kinase inhibitors for treating autoimmune diseases |
| US7727731B2 (en) | 2001-06-29 | 2010-06-01 | Ab Science | Potent, selective and non toxic c-kit inhibitors |
| DK1401415T3 (da) | 2001-06-29 | 2006-10-16 | Ab Science | Anvendelse af N-phenyl-2-pyrimidinamin-derivater til behandling af inflammatoriske sygdomme |
| CA2452371A1 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating allergic diseases |
| WO2003002107A2 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms) |
| CA2452171A1 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis |
| JP2004537542A (ja) | 2001-06-29 | 2004-12-16 | アブ サイエンス | 炎症性腸疾患（ｉｂｄ）を治療するための、チロシンキナーゼ阻害剤の使用 |
| CA2452366A1 (en) | 2001-06-29 | 2003-01-16 | Ab Science | Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
| US20030091974A1 (en) | 2001-06-29 | 2003-05-15 | Alain Moussy | Method for screening compounds capable of depleting mast cells |
| WO2003002105A2 (en) | 2001-06-29 | 2003-01-09 | Ab Science | Use of tyrosine kinase inhibitors for treating bone loss |
| JP2005507916A (ja) | 2001-09-20 | 2005-03-24 | アブ サイエンス | 細菌感染症を治療するための、強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤の使用方法 |
| EP1461032B1 (en) | 2001-09-20 | 2008-07-16 | AB Science | Use of c-kit inhibitors for promoting hair growth |
| JP2005511596A (ja) | 2001-09-20 | 2005-04-28 | アブ サイエンス | ヒトの皮膚を白くし、且つメラノサイト機能不全関連疾病を治療するためのチロシンキナーゼ阻害剤の使用方法 |
| JP2005526048A (ja) | 2002-02-27 | 2005-09-02 | アブ サイエンス | Ｃｎｓ疾患を治療するためのチロシンキナーゼ阻害剤の使用方法 |
| DE60323613D1 (de) | 2002-02-27 | 2008-10-30 | Ab Science | Verwendung von tyrosinkinase-hemmern zur behandlung von erkrankungen im zusammenhang mit substanzgebrauch |
| MXPA04011579A (es) * | 2002-05-29 | 2005-03-07 | Amgen Inc | Derivados de 2-oxo-2,3,4-trihidroquinazolinilo para el tratamiento de trastornos relacionados con la proliferacion celular. |
| US20050239852A1 (en) | 2002-08-02 | 2005-10-27 | Ab Science | 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| SE0202462D0 (sv) * | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel use |
| MXPA05008309A (es) * | 2003-02-10 | 2005-09-20 | Amgen Inc | Ligandos de receptor vaniloide y su uso en tratamientos. |
| DE602004013283D1 (de) | 2003-02-27 | 2008-06-05 | Ab Science | Diagnostisches verfahren der mastozytose |
| FR2854158B1 (fr) * | 2003-04-25 | 2006-11-17 | Sanofi Synthelabo | Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique |
| JP2007500725A (ja) * | 2003-07-29 | 2007-01-18 | アイアールエム・リミテッド・ライアビリティ・カンパニー | プロテインキナーゼ阻害剤としての化合物および組成物 |
| CA2535242A1 (en) | 2003-08-15 | 2005-02-24 | Ab Science | Use of c-kit inhibitors for treating type ii diabetes |
| US7363881B2 (en) | 2003-11-06 | 2008-04-29 | Nova-Tech Engineering, Inc. | Beak treatment with tongue protection |
| PT1702917T (pt) | 2003-12-25 | 2017-11-14 | Nippon Shinyaku Co Ltd | Derivado de amida e medicamento |
| US7650848B2 (en) * | 2004-02-17 | 2010-01-26 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
| WO2005115385A1 (en) * | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating acne |
| TW200702876A (en) * | 2005-07-04 | 2007-01-16 | Avermedia Tech Inc | Projector device capable of sychronously encoding audio and video to become AV sychronous paly file |
-
2008
- 2008-02-13 KR KR1020097016822A patent/KR20090110851A/ko not_active Application Discontinuation
- 2008-02-13 WO PCT/EP2008/051704 patent/WO2008098949A2/en active Application Filing
- 2008-02-13 AR ARP080100620A patent/AR065337A1/es active IP Right Grant
- 2008-02-13 MX MX2009008665A patent/MX2009008665A/es active IP Right Grant
- 2008-02-13 EP EP11170200.7A patent/EP2366703B1/en active Active
- 2008-02-13 AT AT08708929T patent/ATE515506T1/de not_active IP Right Cessation
- 2008-02-13 EP EP08708929A patent/EP2118099B1/en active Active
- 2008-02-13 SI SI200830399T patent/SI2118099T1/sl unknown
- 2008-02-13 CA CA2970628A patent/CA2970628C/en active Active
- 2008-02-13 CA CA2677586A patent/CA2677586C/en active Active
- 2008-02-13 US US12/526,827 patent/US8153792B2/en active Active
- 2008-02-13 RU RU2009132186/04A patent/RU2456285C2/ru active
- 2008-02-13 TW TW097105021A patent/TWI406862B/zh not_active IP Right Cessation
- 2008-02-13 ES ES11170200.7T patent/ES2522169T3/es active Active
- 2008-02-13 NZ NZ578944A patent/NZ578944A/en unknown
- 2008-02-13 BR BRPI0807626-0A patent/BRPI0807626B1/pt active IP Right Grant
- 2008-02-13 PL PL11170200T patent/PL2366703T3/pl unknown
- 2008-02-13 SI SI200831294T patent/SI2366703T1/sl unknown
- 2008-02-13 CN CN2008800049044A patent/CN101657446B/zh active Active
- 2008-02-13 AU AU2008214679A patent/AU2008214679A1/en not_active Abandoned
- 2008-02-13 PL PL08708929T patent/PL2118099T3/pl unknown
- 2008-02-13 ES ES08708929T patent/ES2369617T3/es active Active
- 2008-02-13 JP JP2009549405A patent/JP5568312B2/ja active Active
- 2008-02-13 CN CN201310141370.2A patent/CN103342701B/zh active Active
-
2009
- 2009-08-10 IL IL200320A patent/IL200320A0/en unknown
- 2009-08-11 TN TNP2009000342A patent/TN2009000342A1/fr unknown
- 2009-08-11 MA MA32161A patent/MA31180B1/fr unknown
- 2009-08-28 ZA ZA2009/05981A patent/ZA200905981B/en unknown
-
2011
- 2011-10-05 HR HR20110709T patent/HRP20110709T1/hr unknown
-
2012
- 2012-03-08 US US13/415,249 patent/US8492545B2/en active Active
- 2012-04-12 RU RU2012114234/04A patent/RU2491286C1/ru active
-
2013
- 2013-05-10 US US13/891,639 patent/US8940894B2/en active Active
- 2013-05-30 JP JP2013113789A patent/JP5784073B2/ja active Active
-
2014
- 2014-10-15 HR HRP20140986AT patent/HRP20140986T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR065337A1 (es) | Proceso para la sintesis de compuestos de 2- aminotiazol como inhibidores de quinasa, forma polimorfica | |
| AR062125A1 (es) | Compuestos que modulan el receptor cb2 y su utilizacion como medicamentos | |
| NO20081464L (no) | 1-heterocyklusulfonyl, 2-aminometyl, 5-(hetero-)aryl subsidiert 1-H-pyrrol-derivater som syresekresjonsinhibitorer | |
| CO6280530A2 (es) | Derivados de pirimidina 5-fluoro como fungicidas | |
| DOP2010000194A (es) | Derivados de oxadiazol activos sobre fosfato de esfingosina-1 | |
| TW200942541A (en) | Polysubstituted 6-heteroarylimidazo[1,2-α]pyridine derivatives, preparation thereof and therapeutic use thereof | |
| PE20090290A1 (es) | Derivados de pirrolopiridina como inhibidores de bace | |
| HRP20201727T1 (hr) | 2-((5-(1-(3-(metilsulfonil)propil)piperidin-4-il)piridin-2-il)amino)pirido[2,3-d]pirimidin-7(8h)-on derivati i srodni spojevi kao cdk4 inhibitori za liječenje tumora | |
| DE602005023343D1 (de) | Pyrimidinderivate als gpcr-agonisten | |
| NO20070032L (no) | Hetroarylbenzamid-derivater for anvendelse som GLK-aktivatorer ved behandling av diabetes | |
| WO2007149448A3 (en) | Pyrazinones as cellular proliferation inhibitors | |
| NO20070731L (no) | Heterocykliske forbindelser. | |
| NO20064008L (no) | Forbindelser | |
| AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
| JP2012522763A5 (es) | ||
| RU2017103753A (ru) | Производное пиридона, имеющее тетрагидропиранилметильную группу | |
| KR20160067841A (ko) | 헤테로사이클릭 화합물 및 사용 방법 | |
| CR10722A (es) | Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3 | |
| MY153042A (en) | Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors | |
| SG172229A1 (en) | Thiazolyl-benzimidazoles | |
| CR11578A (es) | Derivados de oxadiazol activos e 1-fosfato de esfingosina | |
| RU2015139700A (ru) | Трициклические гетероциклические соединения в качестве противораковых средств | |
| JP2013540738A5 (es) | ||
| TN2009000511A1 (en) | Sulfonyl-quinoline derivatives | |
| EA200201055A1 (ru) | Новый стабильный кристалл производного тиазолидиндиона и способ его получения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |